Literature DB >> 2174410

Effects of dietary supplementation with eicosapentaenoic acid or gamma-linolenic acid on neutrophil phospholipid fatty acid composition and activation responses.

M P Fletcher1, V A Ziboh.   

Abstract

Previous data that alimentation with fish oil rich in eicosapentaenoic acid (EPA; 20:n-3) or vegetable oil rich in gamma-linolenic acid (GLA; 18:3n-6) can reduce symptoms of inflammatory skin disorders lead us to determine the effects of dietary supplements of oils rich in EPA or GLA on guinea pig (GP) neutrophil (PMN) membrane potential (delta gamma), secretion, and superoxide (O2-) responses. Weanling GPs were initially fed diets supplemented with olive oil (less than 0.1% EPA; less than 0.1% GLA) for 2 weeks, followed by a crossover by two sets of animals to diets supplemented with fish oil (19% EPA) or borage oil (25% GLA). At 4-week intervals, 12% sterile casein-elicited peritoneal neutrophils (PMN) were assessed for membrane polyunsaturated fatty acid (PUFA) profiles and FMLP-, LTB4-, and PMA-stimulated delta gamma changes, changes in flow cytometrically measured forward scatter (FWD-SC) (shape change), 90 degrees scatter (90 degrees -SC) in cytochalasin B-pretreated-PMN (secretion response), and superoxide responses, GP incorporated EPA and GLA (as the elongation product, dihomo-GLA or DGLA) into their PMN phospholipids by 4 weeks. The peritoneal PMN of all groups demonstrated broad resting FWD-SC and poor activation-related FWD-SC increases, suggesting in vivo activation. While secretion was comparable in the three groups in response to FMLP, there was a trend toward inhibition of LTB4-stimulated 90 degrees -SC loss in both fish and borage oil groups. This was significant only with borage oil (21.7 +/- 2.1 vs 15.3 +/- 1.2% loss of baseline 90 degrees -SC, olive vs borage: P = 0.03). PMN from borage- and fish oil-fed GPs showed a progressively lower O2- response to FMLP than the olive oil group (73.9 +/- 3.9 and 42.9 +/- 6.8% of olive oil response for borage and fish oils, respectively; P less than 0.005 and P less than 0.01, respectively, at 12 weeks), while PMA-stimulated O2- was inhibited only in the fish oil-fed group and only at 12 weeks (62.0 +/- 2.7% of control; P less than 0.025). We conclude that dietary supplementation with oils rich in PUFAs can modify PMN activation responses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174410     DOI: 10.1007/BF00914278

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  20 in total

1.  Dietary supplementation with oils rich in (n-3) and (n-6) fatty acids influences in vivo levels of epidermal lipoxygenase products in guinea pigs.

Authors:  C C Miller; V A Ziboh; T Wong; M P Fletcher
Journal:  J Nutr       Date:  1990-01       Impact factor: 4.798

2.  Modulation of the heterogeneous membrane potential response of neutrophils to N-formyl-methionyl-leucyl-phenylalanine (FMLP) by leukotriene B4: evidence for cell recruitment.

Authors:  M P Fletcher
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

Review 3.  Prostaglandins, immune responses, and murine lupus.

Authors:  R B Zurier
Journal:  Arthritis Rheum       Date:  1982-07

Review 4.  Complement-induced granulocyte aggregation: an unsuspected mechanism of disease.

Authors:  H S Jacob; P R Craddock; D E Hammerschmidt; C F Moldow
Journal:  N Engl J Med       Date:  1980-04-03       Impact factor: 91.245

5.  Effects of dietary supplementation of fish oil on neutrophil and epidermal fatty acids. Modulation of clinical course of psoriatic subjects.

Authors:  V A Ziboh; K A Cohen; C N Ellis; C Miller; T A Hamilton; K Kragballe; C R Hydrick; J J Voorhees
Journal:  Arch Dermatol       Date:  1986-11

6.  The protective effect of dietary fish oil on murine lupus.

Authors:  D R Robinson; J D Prickett; R Polisson; A D Steinberg; L Levine
Journal:  Prostaglandins       Date:  1985-07

7.  Enhancement of neutrophil function by granulocyte-macrophage colony-stimulating factor involves recruitment of a less responsive subpopulation.

Authors:  M P Fletcher; J C Gasson
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

8.  Human neutrophil heterogeneity identified using flow microfluorometry to monitor membrane potential.

Authors:  B Seligmann; T M Chused; J I Gallin
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

9.  Oxidative metabolism of dihomogammalinolenic acid by guinea pig epidermis: evidence of generation of anti-inflammatory products.

Authors:  C C Miller; C A McCreedy; A D Jones; V A Ziboh
Journal:  Prostaglandins       Date:  1988-06

10.  Prostaglandin E1 inhibits N-formyl-methionyl-leucyl-phenylalanine-mediated depolarization responses by decreasing the proportion of responsive cells without affecting chemotaxin-induced forward light scatter changes.

Authors:  M P Fletcher
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

View more
  4 in total

Review 1.  Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain.

Authors:  Artemis P Simopoulos
Journal:  Mol Neurobiol       Date:  2011-01-29       Impact factor: 5.590

2.  Changes of fatty acid composition and oxidative metabolism of human neutrophils migrating into an inflammatory exudate.

Authors:  A Carletto; P Bellavite; P Guarini; D Biasi; S Chirumbolo; P Caramaschi; L M Bambara; R Corrocher
Journal:  Inflammation       Date:  1996-04       Impact factor: 4.092

Review 3.  Gamma-linolenic acid, Dihommo-gamma linolenic, Eicosanoids and Inflammatory Processes.

Authors:  Susan Sergeant; Elaheh Rahbar; Floyd H Chilton
Journal:  Eur J Pharmacol       Date:  2016-04-12       Impact factor: 4.432

4.  Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults.

Authors:  F Thies; E A Miles; G Nebe-von-Caron; J R Powell; T L Hurst; E A Newsholme; P C Calder
Journal:  Lipids       Date:  2001-11       Impact factor: 1.880

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.